Zacks Investment Research upgraded shares of Celcuity (NASDAQ:CELC) from a hold rating to a buy rating in a research report sent to investors on Monday morning, Zacks.com reports. They currently have $25.00 target price on the stock.
According to Zacks, “Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. “
CELC has been the subject of several other reports. ValuEngine upgraded shares of Celcuity from a hold rating to a buy rating in a research note on Friday, March 15th. HC Wainwright set a $36.00 target price on shares of Celcuity and gave the company a buy rating in a research note on Wednesday, May 8th.
CELC opened at $22.45 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 26.94 and a current ratio of 26.94. Celcuity has a 1 year low of $18.28 and a 1 year high of $31.00.
Celcuity (NASDAQ:CELC) last posted its earnings results on Tuesday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. On average, sell-side analysts predict that Celcuity will post -0.81 EPS for the current year.
A number of large investors have recently bought and sold shares of CELC. Vanguard Group Inc raised its position in Celcuity by 59.8% during the third quarter. Vanguard Group Inc now owns 259,900 shares of the company’s stock worth $7,475,000 after acquiring an additional 97,266 shares during the period. Vanguard Group Inc. raised its position in Celcuity by 59.8% during the third quarter. Vanguard Group Inc. now owns 259,900 shares of the company’s stock worth $7,475,000 after acquiring an additional 97,266 shares during the period. ARS Investment Partners LLC raised its position in Celcuity by 48.2% during the fourth quarter. ARS Investment Partners LLC now owns 71,093 shares of the company’s stock worth $1,706,000 after acquiring an additional 23,119 shares during the period. JNBA Financial Advisors acquired a new position in Celcuity during the fourth quarter worth $498,000. Finally, Renaissance Technologies LLC acquired a new position in Celcuity during the third quarter worth $336,000. Institutional investors own 21.95% of the company’s stock.
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Recommended Story: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.